11 August 2022 · Levobupivacaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Vancomycin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Amikacin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Thiotepa products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
29 June 2022 · Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
29 June 2022 · Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance
29 June 2022 · Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
16 June 2022 · Topical chloramphenicol can be used with caution and monitoring. Systemic chloramphenicol is not recommended. Advice applies to full term and healthy infants.
13 June 2022 · Guidance to help you ensure your patients with Parkinson’s Disease are able to get the most from their medicines if they develop swallowing difficulties
28 April 2022 · Hormone Replacement Therapy availability varies currently. Check for available products and keep up-to-date. Supply content is maintained regularly by DHSC.